Biodexa Pharmaceuticals PLC (BDRX) Quote

BDRX: Heck, last time I saw an iHub board THIS quiet, was on the AAPL board when Steve Jobs croaked!!

SONG BREAK:

Well, looks to have caught a bid.

We shall see if $2 is still going to hit.

The financing from December was at $2.00 per share. (Per ADS share).

I only chose the $2 mark because that is were they did an offering ... not because I thought it deserved to hit the next dollar mark.

Looks like exchange ratio is 1:400

Meaning 3 million shares.

Why? The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2023 was: 1,189,577,722 Ordinary Shares

Hmmm... this sounds like fantastic news.

So, why is is still below $2?

Explain to me like I buy stocks to generate income? (ELI0)

FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery
Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas (“CPRIT”) in a competitive process
Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24
Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25
Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health
$BDRX

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the
Treatment of Familial Adenomatous Polyposis (FAP)

Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP

An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum

In FAP, eRapa holds the potential of delaying or preventing surgical intervention

Multiple opportunities seen in other indications, including bladder and prostate cancers

FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery
Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas (“CPRIT”) in a competitive process
Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24
Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25
Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced it entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) (“Emtora”) for the rights to eRapa under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa.

Stephen Stamp, CEO and CFO of Biodexa said, “Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa’s oncology pipeline and adds numerous valuation catalysts for our stakeholders. We are delighted to be working with the Emtora team which has excelled in bringing eRapa close to the end of Phase 2 in Non-muscle Invasive Bladder Cancer and to the beginning of a Phase 3 trial in FAP, a devastating disease for which there is currently no approved pharmacological agent for altering its progression. Left untreated, it almost always leads to incredibly invasive surgery and a major deterioration in the quality of life.”

Stephen Dufilho, Executive Chairman of Emtora added, “The transaction with Biodexa is the culmination of a decade-long effort to advance our potentially game-changing eRapa to a registrational Phase 3 trial - and ultimately to patients in need. Our story began in San Antonio – where eRapa was originally invented at the University of Texas and funded in part by grants from the Cancer Prevention Research Institute of Texas. We thank the scientists, clinicians, investors and biotech executives that supported our efforts to reach this important milestone. We look forward to working with the Biodexa team as we embark upon this next chapter.”

About eRapa
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis1. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035.

eRapa in FAP
FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP typically leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported incidence of one in 5,000 to 10,000 in the US2 and one in 11,300 to 37,600 in Europe3. eRapa has received Orphan Designation in the US with plans to seek such designation in Europe. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP.

Emtora is currently completing an open-label, multi-center Phase 2 study in 30 patients with confirmed FAP with the primary endpoints of safety and tolerability, and percentage change in polyp burden after six months of treatment with eRapa. The Phase 2 study was partially funded by a $3.0 million grant from CPRIT.

https://twitter.com/search?q=%24bdrx&src=typed_query&f=top

https://www.globenewswire.com/news-release/2024/04/26/2870466/0/en/Biodexa-Enters-Into-Exclusive-License-to-eRapa-a-Phase-3-Ready-Asset-for-the-Treatment-of-Familial-Adenomatous-Polyposis-FAP.html

There will be another price spike in the chart

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

BDRX new 52 lo

$BDRX Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z

#BDRX 🔥 prepare for next week run! $bdrx

BDRX.............................................https://stockcharts.com/h-sc/ui?s=BDRX&p=W&b=5&g=0&id=p86431144783

BDRX...HERE COMES 2.13

Pop

BDRX...2.13 COMING IN

BDRX...DO WE SEE THAT 200 DAY @ 2.13

TRIMMING ABOVE THE 50

BDRX..BREAKING THE 50 DAY

BDRX..HERE WE GO!!!

BDRX...BEST PRE MARKET PLAY...MY AI SCANNER PICKS THE RIGHT ONES!!!

BDRX: Had some rather impressive CANCER news --- & vs. really aggressive Cancers.

BDRX...PRE TO OPEN PLAY!

BDRX under $2

BDRX new 52 week low

Yesterday after hours, shortly before the end, many buyers came in and bought this stock up to $1.89

Could you imagine that today, before the trading session, it would be so relaxed and easily over 4 dollars ?

ah up ?

Up again, let's see where it goes from here!

Yes this stock is trash tbh

I'M DEFINITELY OUT NOW AND THE STOCK IS SHIT AND STILL LANDS IN THE RED ZONE AND I THOUGHT IT WOULD JUMP BACK UP AT THE OPENING OF THE STOCK MARKET AND RUN OVER FOUR DOLLARS LIKE PRE-MARKET BUT YOU CAN FORGET THAT WITH THIS CRAP

Now seems to be the bottom (1.83) and $BDRX could run higher from here.

Hopefully you guys banked on that premarket pop weeeeee $BDRX

🤷🏿‍♂️🐒

This POS

$4 already and great Dip now and how high can $BDRX running today ?

IS THATS THE NEXT 1000% RUNNER ?

4 dollar printing... 😴

$BDRX = a very pretty early riser :)

Well this is a nice way to wake up this morning! 😀

$2 in it to win it

Hit $1.70s

On watch!

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone

New highs tomorrow buckle up!!! $BDRX

BDRX new 52 week low

BDRX new 52 week low

BDRX new 52 week low